Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Federal Court Upholds Assignor Estoppel In Minerva Surgical Case

Executive Summary

A federal circuit court sided with Hologic, validating its patent under assignor estoppel, despite the Supreme Court limiting the principle in a decision last year.

You may also be interested in...

US Supreme Court Limits Estoppel Rule In Minerva Surgical v. Hologic

The ruling keeps the principle of assignor estoppel in place, but limits its use to situations where an inventor’s claims in court directly contradict those in the patent.

US Supreme Court Looks At Inventor Rights In Minerva-Hologic Dispute

The case questions whether inventors should be able to later claim a patent is invalid in court, with justices appearing likely to craft a middle path.

CDC Chooses Five Laboratories For Pathogen Genomics Network

The CDC’s $90m funding will be split among five laborites across the US over five years as a part of its pioneering Pathogen Genomics Centers of Excellence Network.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts